DiaSorin S.p.A. (IT:DIA) has released an update.
DiaSorin S.p.A. reported a strong performance for the first nine months of 2024, with revenues reaching €876 million, a 4% increase at constant exchange rates, and an impressive 7% growth excluding COVID-related sales. The company’s adjusted EBITDA also improved, marking a 6% rise, reflecting a robust profitability trend across all business lines, notably in immunodiagnostics and molecular diagnostics. As a result, DiaSorin has raised its revenue guidance for the 2024 financial year, emphasizing continued growth in non-COVID sectors.
For further insights into IT:DIA stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Super Micro Computer (SMCI) Says Special Committee Found No Evidence of Fraud
- Netflix’s France and Netherlands Offices Raided for Possible Tax Fraud
- Class Action Lawsuit Against Bumble Inc. (NASDAQ:BMBL)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
